|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Investments at fair value | |||||||||||||||
| Non-controlled/non-affiliated company investments, at fair value (amortized cost of $1,510,014 and $1,225,573, respectively) | |||||||||||||||
| Non-controlled/Non-affiliate | |||||||||||||||
| Controlled/affiliate | |||||||||||||||
| Total non-controlled/non-affiliated company investments, at fair value (amortized cost of $1,510,014 and $1,225,573, respectively) | |||||||||||||||
| Investments at fair value (cost of $1,914,134 and $2,001,207, respectively) | |||||||||||||||
| Non-controlled/Non-affiliate | |||||||||||||||
| Controlled/affiliate | |||||||||||||||
| Total investments at fair value (cost of $1,914,134 and $2,001,207, respectively) | |||||||||||||||
| Cash and cash equivalents | |||||||||||||||
| Cash | |||||||||||||||
| Cash equivalents | |||||||||||||||
| Total cash and cash equivalents | |||||||||||||||
| Restricted cash | |||||||||||||||
| Due from adviser expense support (See Note 5) | |||||||||||||||
| Interest receivable | |||||||||||||||
| Derivative assets, at fair value (Note 4) | |||||||||||||||
| Receivable for investments sold | |||||||||||||||
| Contribution receivable | |||||||||||||||
| Prepaid expenses | |||||||||||||||
| Collateral due from broker | |||||||||||||||
| Receivable from controlled/affiliate investments | |||||||||||||||
| Other assets | |||||||||||||||
| Total assets | |||||||||||||||
| Liabilities | |||||||||||||||
| Debt (net of $7,500 and $8,511 deferred financing and issuance costs, respectively, and net of unamortized discount of $271 and $471, respectively) (See Note 7) | |||||||||||||||
| Payable for investments purchased | |||||||||||||||
| Interest payable | |||||||||||||||
| Due to adviser for expense support (See Note 5) | |||||||||||||||
| Incentive fees payable | |||||||||||||||
| Management fees payable | |||||||||||||||
| Derivative liability, at fair value | |||||||||||||||
| Collateral due to broker | |||||||||||||||
| Distributions payable | |||||||||||||||
| Directors’ fees payable | |||||||||||||||
| Accounts payable and accrued expenses | |||||||||||||||
| Total liabilities | |||||||||||||||
| Net Assets: (See Note 9) | |||||||||||||||
| Common shares, $0.01 par value, 500,000,000 and 500,000,000 shares authorized, 49,387,065 and 49,387,065 shares issued and outstanding as of September 30, 2026 and December 31, 2025, respectively | |||||||||||||||
| Paid-in-capital in excess of par value | |||||||||||||||
| Total distributable earnings (loss) | |||||||||||||||
| Total net assets | |||||||||||||||
| Total liabilities and net assets | |||||||||||||||
| Net asset value per share (in dollars per share) | |||||||||||||||
Loading...